1
|
Ryan MJ, Graudins A, O'Shea N, Noghrehchi F, Wong A. Has the rescheduling of modified-release paracetamol in Australia affected the frequency of overdoses? Emerg Med Australas 2024. [PMID: 38529697 DOI: 10.1111/1742-6723.14403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 02/24/2024] [Accepted: 02/29/2024] [Indexed: 03/27/2024]
Abstract
OBJECTIVES In June 2020, modified-release paracetamol (paracetamol-MR) preparations were up-scheduled from schedule-2 (available in pharmacy) to schedule-3 (available by request to a pharmacist only). The present study aims to ascertain whether up-scheduling affected the frequency of paracetamol-MR overdoses. METHODS This is a retrospective cohort study of two data sets from 1 June 2017 to 31 May 2022. Monash Health data were extracted using the diagnosis of paracetamol overdose coding and electronic medical records data. Calls regarding paracetamol-MR overdoses to Victorian Poisons Information Centre (VPIC) were extracted from the Poisons centre call database. We used a quasi-experimental research design with interrupted time series analysis to evaluate the immediate impact and change in trend of poisoning-related calls and ED presentations before and after June 2020. The change in proportion of paracetamol-MR cases in both databases was analysed using the Χ2 test. RESULTS The proportion of paracetamol-MR cases in both data sets did not change. From Monash Health, there was no level change in monthly paracetamol-MR overdose-related presentations following re-scheduling (rate ratio [RR] = 1.08, 95% confidence interval [CI] = 0.57-2.01). There was no change in monthly paracetamol-MR overdose-related calls to VPIC following re-scheduling (RR = 1.05, 95% CI = 0.96-1.14). CONCLUSION The proportion of paracetamol-MR overdoses did not decrease after the up-scheduling to S3. Similarly, the frequency of overdoses by month remained similar. Further limitations on access to paracetamol products may need to be considered.
Collapse
Affiliation(s)
- Michaela J Ryan
- Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
| | - Andis Graudins
- Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
- Monash Toxicology Unit and Emergency Department, Dandenong Hospital, Monash Health, Melbourne, Victoria, Australia
| | - Nicole O'Shea
- Victorian Poisons Information Centre, Austin Health, Melbourne, Victoria, Australia
| | - Firouzeh Noghrehchi
- Translational Australian Clinical Toxicology, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia
| | - Anselm Wong
- Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia
- Department of Critical Care, University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
2
|
Dart RC, Mullins ME, Matoushek T, Ruha AM, Burns MM, Simone K, Beuhler MC, Heard KJ, Mazer-Amirshahi M, Stork CM, Varney SM, Funk AR, Cantrell LF, Cole JB, Banner W, Stolbach AI, Hendrickson RG, Lucyk SN, Sivilotti MLA, Su MK, Nelson LS, Rumack BH. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. JAMA Netw Open 2023; 6:e2327739. [PMID: 37552484 DOI: 10.1001/jamanetworkopen.2023.27739] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/09/2023] Open
Abstract
Importance The US and Canada currently have no formal published nationwide guidelines for specialists in poison information or emergency departments for the management of acetaminophen poisoning, resulting in significant variability in management. Objective To develop consensus guidelines for the management of acetaminophen poisoning in the US and Canada. Evidence Review Four clinical toxicology societies (America's Poison Centers, American Academy of Clinical Toxicology, American College of Medical Toxicology, and Canadian Association of Poison Control Centers) selected participants (n = 21). Led by a nonvoting chairperson using a modified Delphi method, the panel created a decision framework and determined the appropriate clinical management of a patient with acetaminophen poisoning. Unique to this effort was the collection of guidelines from most poison centers in addition to systematic collection and review of the medical literature. Comments from review by external organizations were incorporated before the guideline was finalized. The project began in March 2021 and ended in March 2023. Findings The search retrieved 84 guidelines and 278 publications. The panel developed guidelines for emergency department management of single or repeated ingestion of acetaminophen. In addition, the panel addressed extended-release formulation, high-risk ingestion, coingestion of anticholinergics or opioids, age younger than 6 years, pregnancy, weight greater than 100 kg, and intravenous acetaminophen use. Differences from current US practice include defining acute ingestion as an ingestion presentation from 4 to 24 hours after overdose was initiated. A revised form of the Rumack-Matthew nomogram was developed. The term massive ingestion was replaced with the term high-risk ingestion and denoted by a specific nomogram line. Other recommendations include specific criteria for emergency department triage, laboratory evaluation and monitoring parameters, defining the role of gastrointestinal decontamination, detailed management of acetylcysteine treatment, associated adverse effects, and stopping criteria for acetylcysteine treatment, as well as criteria for consultation with a clinical toxicologist. Finally, specific treatment considerations, including acetylcysteine dosing, fomepizole administration, and considerations for extracorporeal elimination and transplant evaluation, were addressed. Conclusions and Relevance This qualitative study provides a consensus statement on consistent evidence-based recommendations for medical, pharmacy, and nursing education and practice to optimize care of patients with acetaminophen poisoning.
Collapse
Affiliation(s)
- Richard C Dart
- Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, University of Colorado School of Medicine, Denver
| | - Michael E Mullins
- Department of Emergency Medicine, Washington University School of Medicine, St Louis, Missouri
| | | | - Anne-Michelle Ruha
- Banner University Medical Center Phoenix, Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix
| | - Michele M Burns
- Massachusetts/Rhode Island Poison Center, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Karen Simone
- Northern New England Poison Center, Tufts University School of Medicine, Boston, Massachusetts
| | - Michael C Beuhler
- Northern Carolina Poison Control, Atrium Health, Charlotte
- Department of Emergency Medicine, Wake Forest School of Medicine, Salem, North Carolina
| | - Kennon J Heard
- Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, University of Colorado School of Medicine, Denver
| | - Maryann Mazer-Amirshahi
- MedStar Washington Hospital Center, National Capital Poison Center, Georgetown University School of Medicine, Washington, DC
| | - Christine M Stork
- Upstate New York Poison Center, Upstate Medical University, Syracuse
| | - Shawn M Varney
- South Texas Poison Center, University of Texas Health, San Antonio
| | | | - Lee F Cantrell
- Department of Clinical Pharmacy, University of California San Francisco School of Pharmacy, San Francisco
- California Poison Control System, San Diego Division, University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego
| | - Jon B Cole
- Minnesota Poison Control System, Hennepin Healthcare, University of Minnesota Medical School, Minneapolis
| | | | | | | | - Scott N Lucyk
- Poison and Drug Information Service, University of Calgary Department of Emergency Medicine, Calgary, Alberta, Canada
| | | | - Mark K Su
- New York City Poison Control Center, New York University Grossman School of Medicine, New York
| | - Lewis S Nelson
- Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark
| | - Barry H Rumack
- Department of Emergency Medicine, University of Colorado School of Medicine, Aurora
| |
Collapse
|
3
|
Chiew AL, Buckley NA. Comment on: "population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations". Clin Toxicol (Phila) 2023; 61:139-140. [PMID: 36264046 DOI: 10.1080/15563650.2022.2135519] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Affiliation(s)
- A L Chiew
- Clinical Toxicology Unit, Prince of Wales Hospital, Randwick, Australia
- New South Wales Poisons Information Centre, Children's Hospital at Westmead, Westmead, Australia
| | - N A Buckley
- New South Wales Poisons Information Centre, Children's Hospital at Westmead, Westmead, Australia
- Discipline of Biomedical Informatics and Digital Health, The University of Sydney, Sydney, Australia
| |
Collapse
|
4
|
Spyker DA. The authors' reply to comment on "Population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations". Clin Toxicol (Phila) 2023; 61:140-141. [PMID: 36752691 DOI: 10.1080/15563650.2022.2142603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Affiliation(s)
- Daniel A Spyker
- Adjunct Assistant Professor of Emergency Medicine, Oregon Health & Science University, Portland, OR
| |
Collapse
|
5
|
Janković SM. Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens. Expert Opin Drug Metab Toxicol 2022; 18:745-753. [PMID: 36420805 DOI: 10.1080/17425255.2022.2151893] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
INTRODUCTION Although N-acetyl-cysteine (NAC) has long been used for the treatment of acetaminophen poisoning/overdose, the optimal NAC dosing regimen for varying patterns or severity of the poisoning/overdose is still unknown. AREAS COVERED Relevant literature was searched for in the MEDLINE (from 1964 until August 31st, 2022), SCOPUS (from 2004 until August 31st, 2022) and GOOGLE SCHOLAR (from 2004 until August 31st, 2022) databases, without restriction in terms of publication date. The inclusion criteria were: original clinical studies reporting results, and studies investigating efficacy and safety of NAC dosing regimens in case(s) of overdose or poisoning with acetaminophen. EXPERT OPINION For a more effective treatment of acetaminophen poisoning in the future, it will be crucial to advance the technology of measuring acetaminophen, its metabolites and NAC in the serum, preferably with the point-of-care technique, so that in real time it can be continuously assessed whether it is necessary to administer NAC, and further to increase the dose of NAC and extend the duration of its administration, or not.
Collapse
|
6
|
Extended Release Acetaminophen Overdose With Delayed Peak Concentrations. Am J Ther 2022; 29:e655-e656. [PMID: 33491964 DOI: 10.1097/mjt.0000000000001329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
7
|
Spyker DA, Dart RC, Yip L, Reynolds K, Brittain S, Yarema M. Population pharmacokinetic analysis of acetaminophen overdose with immediate release, extended release and modified release formulations. Clin Toxicol (Phila) 2022; 60:1113-1121. [PMID: 36106921 DOI: 10.1080/15563650.2022.2114361] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
OBJECTIVES The introduction of delayed release formulations of acetaminophen (APAP) has created concern about the role of formulation in overdose. We examined the APAP overdose pharmacokinetic (PK) profiles to assess the role of dose, coingestants and formulation: immediate release (IR), extended release (ER), and modified release (MR) on APAP pharmacokinetic measures. METHODS We collected by-subject APAP PK data: subject description, timed blood APAP concentrations, dose, and coingestants. We sought both overdose and randomized controlled trials (RCTs) for supratherapeutic doses involving ER or MR formulations. Data analysis and simulation used the non-linear mixed-effects modeling program NONMEM-version 7.4. RESULTS The final dataset comprised 3,033 [APAP] from 356 subjects and 15 sources including 3 RCTs (179 subjects receiving IR, 122 ER, 65 MR). The final population PK (PopPK) model was a linear 2-compartment model with first-order (oral) absorption. Covariate relationships included: APAP absorption rate and bioavailability decreased with increased oral dose (p < 0.00005) for all 3 formulations (MR > ER > IR). Post hoc analyses showed opioid coingestant increased exposure (area under the curve, AUC) by factor of 1.6. Simulations of 100 g vs 10 g doses for IR, ER and MR showed overdose of the ER formulation exhibits slower absorption and lower Cmax, overall exposure (AUC) is less than 80% of an equivalent dose of IR acetaminophen. The overall exposure for the MR formulation is less than 70% of an equivalent dose of IR. CONCLUSIONS Acetaminophen ER and MR formulations have slower absorption and decreased bioavailability leading to a lower Cmax and later Tmax than the IR formulation. These results have potential clinical implications because delayed absorption could confound use of the Rumack-Matthew nomogram by underestimating the severity of ingestion early in the course of treatment.
Collapse
Affiliation(s)
| | | | - Luke Yip
- Rocky Mountain Poison and Drug Center, Denver, CO, USA
| | - Kate Reynolds
- Rocky Mountain Poison and Drug Center, Denver, CO, USA
| | | | - Mark Yarema
- Poison and Drug Information Service, Calgary, Alberta, CA, USA
| |
Collapse
|
8
|
Abstract
Acetaminophen is a common medication taken in deliberate self-poisoning and unintentional overdose. It is the commonest cause of severe acute liver injury in Western countries. The optimal management of most acetaminophen poisonings is usually straightforward. Patients who present early should be offered activated charcoal and those at risk of acute liver injury should receive acetylcysteine. This approach ensures survival in most. The acetaminophen nomogram is used to assess the need for treatment in acute immediate-release overdoses with a known time of ingestion. However, scenarios that require different management pathways include modified-release, large/massive, and repeated supratherapeutic ingestions.
Collapse
Affiliation(s)
- Angela L Chiew
- Clinical Toxicology Unit, Prince of Wales Hospital, Barker Street, Randwick, New South Wales 2031, Australia.
| | - Nicholas A Buckley
- Pharmacology and Biomedical Informatics and Digital Health, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales 2050, Australia
| |
Collapse
|
9
|
Li J, Chiew AL, Isbister GK, Duffull SB. Population pharmacokinetics of immediate-release and modified-release paracetamol and its major metabolites in a supratherapeutic dosing study. Clin Toxicol (Phila) 2021; 60:25-32. [PMID: 34080498 DOI: 10.1080/15563650.2021.1928163] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVES Overdose with paracetamol modified-release (MR) formulation, a bilayer tablet containing 69% slow-release component, has been increasing since its introduction to the market. However, little evidence exists for the management of MR paracetamol overdose. We aimed to develop a population pharmacokinetic (PK) model for immediate-release (IR) and MR paracetamol and its major metabolism, and quantitatively understand the formulation difference in toxicity assessment based on the nomogram line. METHODS Data from a cross-over study design in nine healthy volunteers administered a single supratherapeutic oral dose (80 mg/kg) of either IR and MR paracetamol were available from a published study. Plasma concentrations for paracetamol and its metabolites glucuronide (APAPG) and sulfate conjugate (APAPS) for both formulations were measured and analysed with population pharmacokinetic (PK) method using NONMEM. Toxicity in both formulations was assessed by comparing the simulated paracetamol concentrations under different paracetamol dose levels with the 150 mg/L nomograms. The difference in the assessment was compared between the two formulations. RESULTS Paracetamol concentrations for the IR formulation were described with a two-compartment model with first-order input and a lag time. The delayed time-course of MR paracetamol concentrations was best captured by a parallel absorption model in which the slow-release component was a serial zero-order then the first-order process. The formation of APAPG was linear, while APAPS concentrations were best fitted by a Michaelis-Menten process. The relative bioavailability of MR paracetamol compared to IR (FMR/IR) was estimated as 0.81. The simulated probability of making different toxicity assessments based on nomogram line was increased with dose levels and was as high as 14.6% after 22 g IR or MR paracetamol ingested. CONCLUSIONS A joint parent-metabolite model to describe time-course profiles of both IR and MR paracetamol and its metabolites APAPG and APAPS concentrations was developed. Simulations from the model showed that toxicity assessment based on the 150 mg/L nomograms is not suitable in MR paracetamol overdoses.
Collapse
Affiliation(s)
- Jingyun Li
- School of Pharmacy, University of Otago, Dunedin, New Zealand
| | - Angela L Chiew
- Emergency Department and Clinical Toxicology, Prince of Wales Hospital and Community Health Services, Randwick, Australia.,NSW Poisons Information Centre, Children's Hospital at Westmead, Westmead, Australia
| | - Geoffrey K Isbister
- NSW Poisons Information Centre, Children's Hospital at Westmead, Westmead, Australia.,Clinical Toxicology Research Group, University of Newcastle, Newcastle, Australia
| | | |
Collapse
|
10
|
Akgun E, Boyacioglu M, Kum S. The potential protective role of folic acid against acetaminophen-induced hepatotoxicity and nephrotoxicity in rats. Exp Anim 2021; 70:54-62. [PMID: 32963203 PMCID: PMC7887621 DOI: 10.1538/expanim.20-0075] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Accepted: 08/19/2020] [Indexed: 12/13/2022] Open
Abstract
Folic acid (FA), is a group B vitamin, has high reactive oxygen radicals quenching ability, resulting in protection against oxidative damage in aerobic cell. Acetaminophen (N-acetyl-p-aminophenol, APAP) is a nonsteroidal anti-inflammatory drug, and can promote oxidative damage in liver and kidney tissues. The aim of this study was to investigate whether folic acid has protective effects on oxidative liver and kidney injury caused by experimental APAP toxication. Forty female Sprague dawley rats were divided into 5 groups; control, APAP, FA, APAP+FA, and APAP+N-acetylcysteine (NAC) groups. APAP toxication was induced by oral gavage (3 g/kg bodyweight). FA (20 mg/kg bodyweight) and NAC (150 mg/kg bodyweight) were given by oral gavage to the specified groups. Oxidant and antioxidant parameter were determined in liver and kidney tissues. In addition, the liver and kidney tissues were histological evaluated. When compared with APAP group, superoxide dismutase (SOD) and catalase activities and glutathione levels were statistically higher, malondialdehyde (MDA) level and myeloperoxidase activity (except liver tissue) were statistically lower in both APAP+FA and APAP+NAC. Liver and kidney MDA level and kidney SOD activity were significantly lower in APAP+NAC group compared with APAP+FA group. Co-administration of NAC with APAP was found to provide protection, but hepatic cords were defective in some places and some glomerular tubules also had dilatation. Necrotic areas was reduced in the liver and the glomerular structure was in good condition in the APAP+FA group. As a result, FA might have a protective effect against APAP-induced hepato-nephrotoxicity and oxidative stress in rat.
Collapse
Affiliation(s)
- Emrah Akgun
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Aydin Adnan Menderes University, Isikli, 09016, Aydin, Turkey
| | - Murat Boyacioglu
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Aydin Adnan Menderes University, Isikli, 09016, Aydin, Turkey
| | - Sadiye Kum
- Department of Histology and Embryology, Faculty of Veterinary Medicine, Aydin Adnan Menderes University, Isikli, 09016, Aydin, Turkey
| |
Collapse
|
11
|
McLachlan S, Kyrimi E, Dube K, Hitman G, Simmonds J, Fenton N. Towards standardisation of evidence-based clinical care process specifications. Health Informatics J 2020; 26:2512-2537. [DOI: 10.1177/1460458220906069] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
There is a strong push towards standardisation of treatment approaches, care processes and documentation of clinical practice. However, confusion persists regarding terminology and description of many clinical care process specifications which this research seeks to resolve by developing a taxonomic characterisation of clinical care process specifications. Literature on clinical care process specifications was analysed, creating the starting point for identifying common characteristics and how each is constructed and used in the clinical setting. A taxonomy for clinical care process specifications is presented. The De Bleser approach to limited clinical care process specifications characterisation was extended and each clinical care process specification is successfully characterised in terms of purpose, core elements and relationship to the other clinical care process specification types. A case study on the diagnosis and treatment of Type 2 Diabetes in the United Kingdom was used to evaluate the taxonomy and demonstrate how the characterisation framework applies. Standardising clinical care process specifications ensures that the format and content are consistent with expectations, can be read more quickly and high-quality information can be recorded about the patient. Standardisation also enables computer interpretability, which is important in integrating Learning Health Systems into the modern clinical environment. The approach presented allows terminologies for clinical care process specifications that were widely used interchangeably to be easily distinguished, thus, eliminating the existing confusion.
Collapse
Affiliation(s)
- Scott McLachlan
- Health informatics and Knowledge Engineering Research Group (HiKER), New Zealand; Queen Mary University of London, UK
| | | | - Kudakwashe Dube
- Health informatics and Knowledge Engineering Research Group (HiKER), New Zealand; Massey University, New Zealand
| | | | | | | |
Collapse
|
12
|
Chiew AL, Reith D, Pomerleau A, Wong A, Isoardi KZ, Soderstrom J, Buckley NA. Updated guidelines for the management of paracetamol poisoning in Australia and New Zealand. Med J Aust 2019; 212:175-183. [DOI: 10.5694/mja2.50428] [Citation(s) in RCA: 30] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Angela L Chiew
- Prince of Wales Hospital and Community Health Services Sydney NSW
- NSW Poisons Information CentreChildren's Hospital at Westmead Sydney NSW
| | | | | | - Anselm Wong
- Victorian Poisons Information CentreAustin Hospital Melbourne VIC
- Monash HealthMonash University Melbourne VIC
| | - Katherine Z Isoardi
- Princess Alexandra Hospital Brisbane QLD
- Queensland Poisons Information CentreQueensland Children's Hospital Brisbane QLD
| | - Jessamine Soderstrom
- Royal Perth Hospital Perth WA
- Western Australia Poisons Information CentreSir Charles Gairdner Hospital Perth WA
| | - Nicholas A Buckley
- NSW Poisons Information CentreChildren's Hospital at Westmead Sydney NSW
- University of Sydney Sydney NSW
| |
Collapse
|
13
|
Kang AM, Padilla-Jones A, Fisher ES, Akakpo JY, Jaeschke H, Rumack BH, Gerkin RD, Curry SC. The Effect of 4-Methylpyrazole on Oxidative Metabolism of Acetaminophen in Human Volunteers. J Med Toxicol 2019; 16:169-176. [PMID: 31768936 DOI: 10.1007/s13181-019-00740-z] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Revised: 09/12/2019] [Accepted: 09/15/2019] [Indexed: 12/11/2022] Open
Abstract
INTRODUCTION Acetaminophen (APAP) is commonly ingested in both accidental and suicidal overdose. Oxidative metabolism by cytochrome P450 2E1 (CYP2E1) produces the hepatotoxic metabolite, N-acetyl-p-benzoquinone imine. CYP2E1 inhibition using 4-methylpyrazole (4-MP) has been shown to prevent APAP-induced liver injury in mice and human hepatocytes. This study was conducted to assess the effect of 4-MP on APAP metabolism in humans. METHODS This crossover trial examined the ability of 4-MP to inhibit CYP2E1 metabolism of APAP in five human volunteers. Participants received a single oral dose of APAP 80 mg/kg, both with and without intravenous 4-MP, after which urinary and plasma oxidative APAP metabolites were measured. The primary outcome was the fraction of ingested APAP excreted as total oxidative metabolites (APAP-CYS, APAP-NAC, APAP-GSH). RESULTS Compared with APAP alone, co-treatment with 4-MP decreased the percentage of ingested APAP recovered as oxidative metabolites in 24-hour urine from 4.48 to 0.51% (95% CI = 2.31-5.63%, p = 0.003). Plasma concentrations of these oxidative metabolites also decreased. CONCLUSIONS These results show 4-MP effectively reduced oxidative metabolism of APAP in human volunteers ingesting a supratherapeutic APAP dose. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT03878693.
Collapse
Affiliation(s)
- A Min Kang
- Division of Clinical Data Analytics and Decision Support, and Division of Medical Toxicology and Precision Medicine, Department of Medicine, University of Arizona College of Medicine - Phoenix, Phoenix, AZ, USA. .,Department of Medical Toxicology, Banner - University Medical Center Phoenix, 1012 E. Willetta St., Fl 2, Phoenix, AZ, 85006, USA.
| | - Angela Padilla-Jones
- Department of Medical Toxicology, Banner - University Medical Center Phoenix, 1012 E. Willetta St., Fl 2, Phoenix, AZ, 85006, USA
| | - Erik S Fisher
- Department of Medical Toxicology, Banner - University Medical Center Phoenix, 1012 E. Willetta St., Fl 2, Phoenix, AZ, 85006, USA
| | - Jephte Y Akakpo
- Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA
| | - Hartmut Jaeschke
- Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA
| | - Barry H Rumack
- Department of Emergency Medicine, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
| | - Richard D Gerkin
- Department of Medical Toxicology, Banner - University Medical Center Phoenix, 1012 E. Willetta St., Fl 2, Phoenix, AZ, 85006, USA
| | - Steven C Curry
- Division of Clinical Data Analytics and Decision Support, and Division of Medical Toxicology and Precision Medicine, Department of Medicine, University of Arizona College of Medicine - Phoenix, Phoenix, AZ, USA.,Department of Medical Toxicology, Banner - University Medical Center Phoenix, 1012 E. Willetta St., Fl 2, Phoenix, AZ, 85006, USA
| |
Collapse
|
14
|
Hendrickson RG. What is the most appropriate dose of N-acetylcysteine after massive acetaminophen overdose? Clin Toxicol (Phila) 2019; 57:686-691. [DOI: 10.1080/15563650.2019.1579914] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Robert G. Hendrickson
- Department of Emergency Medicine, Oregon Health and Science University, Portland, OR, USA
| |
Collapse
|
15
|
Hoegberg LCG, Refsgaard F, Pedersen SH, Personne M, Ullah S, Panagiotidis G, Petersen TS, Annas A. Potential pharmacobezoar formation of large size extended-release tablets and their dissolution – an in vitro study. Clin Toxicol (Phila) 2018; 57:271-281. [DOI: 10.1080/15563650.2018.1513138] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Lotte Christine Groth Hoegberg
- Department of Anaesthesia and Intensive Care, The Danish Poisons Information Centre, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark
| | - Frank Refsgaard
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | - Steen Hauge Pedersen
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
| | - Mark Personne
- The Swedish Poisons Information Centre, Stockholm, Sweden
| | - Shahid Ullah
- Department of Laboratory Medicine, Division of Clinical Pharmacology and Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden
| | - Georgios Panagiotidis
- Department of Laboratory Medicine, Division of Clinical Pharmacology and Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden
| | - Tonny Studsgaard Petersen
- Department of Clinical Pharmacology, The Danish Poisons Information Centre, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark
| | - Anita Annas
- The Swedish Poisons Information Centre, Stockholm, Sweden
| |
Collapse
|
16
|
Chiew AL, Isbister GK, Page CB, Kirby KA, Chan BSH, Buckley NA. Modified release paracetamol overdose: a prospective observational study (ATOM-3). Clin Toxicol (Phila) 2018; 56:810-819. [DOI: 10.1080/15563650.2018.1439950] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Angela L. Chiew
- Clinical Toxicology Unit/Emergency Department, Prince of Wales Hospital, Randwick, NSW, Australia
- Department of Pharmacology, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- New South Wales Poisons Information Centre, The Children’s Hospital at Westmead, Westmead, NSW, Australia
| | - Geoffrey K. Isbister
- New South Wales Poisons Information Centre, The Children’s Hospital at Westmead, Westmead, NSW, Australia
- Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle and Clinical Toxicology Research Group, University of Newcastle, Newcastle, NSW, Australia
| | - Colin B. Page
- Clinical Toxicology Unit, Princess Alexandra Hospital, Brisbane, QLD, Australia
- Queensland Poisons Information Centre, Lady Cilento Children's Hospital, South Brisbane, QLD, Australia
| | - Katharine A. Kirby
- Department of Pharmacology, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
| | - Betty S. H. Chan
- Clinical Toxicology Unit/Emergency Department, Prince of Wales Hospital, Randwick, NSW, Australia
- New South Wales Poisons Information Centre, The Children’s Hospital at Westmead, Westmead, NSW, Australia
| | - Nicholas A. Buckley
- Department of Pharmacology, School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
- New South Wales Poisons Information Centre, The Children’s Hospital at Westmead, Westmead, NSW, Australia
| |
Collapse
|